Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 4/20 | 0.40 |
| ▸ | KLK1 | P06870 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23901934 | 0.89 | NISCH (0.49) | NISCHS1PR1 | |
| SCHEMBL23902193 | 0.84 | PRSS1 (0.55) | NISCHF2PRSS1PRSS2PRSS3 | |
| Hydrochloric Acid SCHEMBL23235854 | 0.83 | PRSS1 (0.54) | NISCHF2PRSS1PRSS2PRSS3 | |
| SCHEMBL23902154 | 0.82 | NISCH (0.51) | NISCHS1PR1 | |
| SCHEMBL23901955 | 0.82 | NISCH (0.41) | F10NISCHPRSS1PRSS2PRSS3 | |
| SCHEMBL23901895 | 0.82 | KLK1 (0.55) | KLK1F2PRSS1PRSS2PRSS3 | |
| Hydrochloric Acid SCHEMBL23235827 | 0.81 | NISCH (0.40) | F10NISCHPRSS1PRSS2PRSS3 | |
| SCHEMBL23902210 | 0.80 | MAOB (0.48) | F10F2PRSS1MAOB | |
| SCHEMBL23902237 | 0.78 | NISCH (0.51) | NISCHMAOBS1PR1 | |
| SCHEMBL23902266 | 0.77 | NISCH (0.53) | NISCHMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | PAM, AMPD1, AMPD3 | F10 2833/4885NISCH 24/4885KLK1 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.